Abstract
Morbidity and mortality from diabetes mellitus (DM) are serious worldwide concerns. By the year 2030, the estimated number of diabetic patients will reach a staggering 439 million worldwide. Diabetes mellitus type 2 (DM2), which involves disturbances in both insulin secretion and resistance, is the most common form of diabetes and affects approximately 5 to 7% of the world's population. When a patient with DM2 cannot regulate his or her blood glucose levels through diet, weight loss, or exercise, oral medications, such as hypoglycemic agents (i.e., sulphonylureas, biguanides, alpha glucosidase inhibitors and thiazolidinediones), are crucial. Here, we discuss some physiological aspects of P2 receptors on pancreatic β-cells, which express a variety of P2 receptor isoforms. These receptors enhance glucose-dependent insulin release. In addition, we speculate on the potential of purinergic compounds as novel or additional treatments for Type 2 Diabetes mellitus.
Keywords: P2 receptors, Diabetes, Antagonists, Pancreatic B-cells
Current Diabetes Reviews
Title:Modulation of P2 Receptors on Pancreatic β-cells by Agonists and Antagonists: A Molecular Target for Type 2 Diabetes Treatment
Volume: 9 Issue: 3
Author(s): Paulo Anastacio Furtado Pacheco, Leonardo Gomes Braga Ferreira, Luiz Anastacio Alves and Robson Xavier Faria
Affiliation:
Keywords: P2 receptors, Diabetes, Antagonists, Pancreatic B-cells
Abstract: Morbidity and mortality from diabetes mellitus (DM) are serious worldwide concerns. By the year 2030, the estimated number of diabetic patients will reach a staggering 439 million worldwide. Diabetes mellitus type 2 (DM2), which involves disturbances in both insulin secretion and resistance, is the most common form of diabetes and affects approximately 5 to 7% of the world's population. When a patient with DM2 cannot regulate his or her blood glucose levels through diet, weight loss, or exercise, oral medications, such as hypoglycemic agents (i.e., sulphonylureas, biguanides, alpha glucosidase inhibitors and thiazolidinediones), are crucial. Here, we discuss some physiological aspects of P2 receptors on pancreatic β-cells, which express a variety of P2 receptor isoforms. These receptors enhance glucose-dependent insulin release. In addition, we speculate on the potential of purinergic compounds as novel or additional treatments for Type 2 Diabetes mellitus.
Export Options
About this article
Cite this article as:
Anastacio Furtado Pacheco Paulo, Gomes Braga Ferreira Leonardo, Anastacio Alves Luiz and Xavier Faria Robson, Modulation of P2 Receptors on Pancreatic β-cells by Agonists and Antagonists: A Molecular Target for Type 2 Diabetes Treatment, Current Diabetes Reviews 2013; 9 (3) . https://dx.doi.org/10.2174/1573399811309030004
DOI https://dx.doi.org/10.2174/1573399811309030004 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glaucoma Disease: A Survey
Current Medical Imaging Recent Development of Anticancer Therapeutics Targeting Akt
Recent Patents on Anti-Cancer Drug Discovery Therapeutic Application of Endothelial Progenitor Cells for Treatment of Cardiovascular Diseases
Current Stem Cell Research & Therapy Angiotensin Converting Enzyme 2 Activator (DIZE) Modulates Metabolic Profiles in Mice, Decreasing Lipogenesis
Protein & Peptide Letters Membrane Ion Channels and Diabetes
Current Pharmaceutical Design High Throughput Metabolomics in Clinical Studies: Review and New Applications to Remote Ischemic Preconditioning
Current Topics in Medicinal Chemistry Therapeutic Implications of Beta-Adrenergic Receptor Pharmacodynamic Properties
Current Clinical Pharmacology Contemporary Review of Drugs Used to Treat Obesity
Cardiovascular & Hematological Agents in Medicinal Chemistry Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients
Current Vascular Pharmacology Pathogenesis of the Podocytopathy and Proteinuria in Diabetic Glomerulopathy
Current Diabetes Reviews The Vascular Component of Alzheimer`s Disease
Current Neurovascular Research Gut Microbiota as a Therapeutic Target for Metabolic Disorders
Current Medicinal Chemistry Androgen Deficiency in Aging Male Questionnaire for the Clinical Detection of Testosterone Deficiency in a Population of Black Sub-Saharan African Men with Type 2 Diabetes Mellitus: Is it a Reliable Tool?
Current Diabetes Reviews The Association between Labor Induction and Autism Spectrum Disorders Among Children: A Meta-Analysis
Current Pediatric Reviews The Role of H. pylori Infection in Diabetes
Current Diabetes Reviews Hepatoprotective Effects of Resveratrol in Non-Alcoholic Fatty Live Disease
Current Pharmaceutical Design Enzymatic Vitreolysis
Current Diabetes Reviews Social Determinants of Childhood Obesity: Beyond Individual Choices
Current Pediatric Reviews Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Five Years Patenting Time Frame Concerning Enzymatic Preparation of Glycosides
Recent Patents on Biotechnology